

CITATION REPORT

List of articles citing

New drug approvals in oncology

DOI: 10.1038/s41571-019-0313-2

Nature Reviews Clinical Oncology, 2020, 17, 140-146.

Source: <https://exaly.com/paper-pdf/84850003/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Klinische Endpunkte in Studien. 2020 , 35, 368-372	0.2	2
19	Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1943-1953	4	3
18	Overcoming cancer therapeutic bottleneck by drug repurposing. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 113	21	131
17	Ethics of Pharma Clinical Trials in the Era of Precision Oncology. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021 , 36, 1-9	3.9	0
16	The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
15	Human iPSCs in Cardiovascular Research: Current Approaches in Cardiac Differentiation, Maturation Strategies, and Scalable Production. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
14	Microfluidics for Drug Development: From Synthesis to Evaluation. <i>Chemical Reviews</i> , 2021 , 121, 7468-7529	52.1	22
13	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). <i>Clinical and Translational Oncology</i> , 2021 , 23, 2489-2496	3.6	0
12	The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine. <i>Cancers</i> , 2021 , 13,	6.6	
11	Primary tumor surgery improves survival of cancer patients with synchronous solitary bone metastasis: a large population-based study. <i>Annals of Translational Medicine</i> , 2021 , 9, 31	3.2	0
10	Harnessing the predictive power of preclinical models for oncology drug development. <i>Nature Reviews Drug Discovery</i> , 2021 ,	64.1	3
9	Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process.. <i>ESMO Open</i> , 2022 , 7, 100379	6	0
8	Drug repurposing: An emerging strategy in alleviating skin cancer.. <i>European Journal of Pharmacology</i> , 2022 , 175031	5.3	1
7	Application of histology-agnostic treatments in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	0
6	Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. <i>Journal of Hematology and Oncology</i> , 2022 , 15,	22.4	4
5	New-onset cancer cases in FDA's Sentinel System: a large distributed system of US electronic healthcare data. <i>Cancer Epidemiology Biomarkers and Prevention</i> ,	4	
4	Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States. 12,		0

3 De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. **2022**, 215837

2 RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study. 3, ○

1 Discovery of anticancer therapeutics: Computational chemistry and Artificial Intelligence-assisted approach. **2023**, 19-41 ○